Volume: 8 Issue: 3
Year: 2020, Page: 60-65, Doi: https://doi.org/10.47799/pimr.0803.13
Received: Nov. 16, 2020 Accepted: Dec. 2, 2020 Published: Dec. 2, 2020
Background: There are limitations of histomorphology in the appropriate categorization of lung carcinoma where immunohistochemistry can confirm the morphological diagnosis and may add value in the poorly differentiated and undifferentiated tumors. The aim of the study was to assess the role of immunohistochemistry in classifying lung carcinoma on small biopsy samples.
Methods and Material: A retrospective hospital based, observational study was conducted on cases of lung carcinoma diagnosed by core needle or bronchoscopic biopsies over a 3- year period. After evaluation of clinical findings and H&E sections, all biopsies were evaluated by immunohistochemical staining. The immunohistochemistry panel included cytokeratin cocktail, CK7, CK 20, TTF1, Napsin A, CK5/6, p40, synaptophysin, chromogranin, CD 56.
Result: Out of 78 cases, the mean age was 58 +/- 11 years. Most prevalent malignancy type was adenocarcinoma (30, 38.1%). Adenocarcinoma cases were positive for CK7 (25/26, 96%), Napsin A (24/26, 92%), TTF1 (15/30, 50%) and negative for CK 20. Squamous cell carcinoma cases showed positivity for p40(18/22, 82%) and CK 5/6 (17/22.71%).Small cell carcinoma showed positivity for neuroendocrine markers synaptophysin (5/7,71%) and chromogranin(4/7, 57%) and CD 56 (6/7cases (85%).88% of small cell carcinomas,75% of adenocarcinomas and 72 % of squamous cell carcinomas were accurately diagnosed by morphology. Morphologic prediction was poor in the NSCC NOS group (0%) and poorly differentiated carcinomas (64%), which were finally, diagnosed by immunohistochemistry.In the morphologically diagnosed cases, immunohistochemistry confirmed the diagnosis.
Conclusion: Thus, morphology added with immunohisto chemistry provides a crisp diagnosis thereby improving therapeutic efficacy.
Keywords: immunohistochemistry, lung carcinoma, morphology, small biopsy.
1. Global Cancer Observatory. International Agency for Research on Cancer. Population Fact Sheets. [Last accessed on 2018 Nov 29]. Available from: http://www.gco.iarc.fr/ today/data/factsheets/cancers/15-Lung-fact-sheet.pdf .
2. Global Cancer Observatory. International Agency for Research on Cancer. Cancer Fact Sheets. [Last accessed on 2018 Nov 29]. Available from: http://www.gco.iarc.fr/today/data/factsheets/ populations/356-india-fact-sheets.pdf .
3. Jafarian A H, Gharib M, Roshan N M, Sherafatnia S, Omidi A A, Bagheri S .The Diagnostic Value of TTF-1, P63, HMWK, CK7, and CD56 Immunostaining in the Classification of Lung Carcinoma .Iran J Pathol 2017;12:195-201
4. Jing J, Konopka K E. Diagnosis of lung carcinoma on small biopsy Surgical Pathology Clinics 2020;13:1-15
5. Travis W D, Brambilla E,. Nicholson A G, Yatabe Y, Austin J H M,et al. The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic AdvancesSince the 2004 Classification. J Thorac Oncol. 2015;10: 1243–60
6. Travis W D, Brambilla E, Noguchi M, Nicholson A G, Geisinger K et al. Diagnosis of Lung Cancer in Small Biopsies and Cytology Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med. 2013;137:668-84.
7. Malik P S , Sharma M C , Mohanti B K , Shukla K N , Deo SVS , Mohan A , Kumar G , Raina V. Clinico-pathological Profile of Lung Cancer at AIIMS: A Changing Paradigm in India. Asian Pacific Journal of Cancer Prevention2013;14:489-94
8. Bhatti V, Kwatra KS,Puri S,Calton N. Histopathological spectrum and immunohistochemical profile of lung carcinomas: A 9-year study from a tertiary hospital in North India. Int J Appl Basic Med Res 2019;9:169–75.
9. Dey A, Biswas D, Saha S K, Kundu S, Kundu S, Sengupta A. Comparison study of clinicoradiological profile of primary lung cancer cases: An Eastern India experience. Indian J Cancer 2012;49:89-95.
10. Mukhopadhyay S, Katzenstein A L A. Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on BiopsySpecimens: Utility of an Immunohistochemical Panel Containing TTF-1, Napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15–25.
11. Stojsic J, Jovanic I, Markovic J, Gajic M. Contribution of immunohistochemistry in the differential diagnosis of non-small cell lung carcinomas on small biopsy samples.J BUON 2013;18:176-87
12. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.
13. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184–91.
14. Bishop J A, Feldstein J T, Westra W H, Pelosi G, Travis W D, Rekhtman N. p40 (DNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathology .2012; 25: 405–15.
© 2020-21 Prathima Institue of Medical Sciences
Mallick D , Kundu S, Chakrabarti S, Gayen P. The Significant Impact of Immunohistochemistry in the Classification of Lung Carcinoma on Small Biopsies.Perspectives in Medical Research 2020; 8 (3):60-65 DOI: 10.47799/pimr.0803.13